Anti-Obesity Drugs Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032
CHAPTER 1. Industry Overview of Anti-Obesity Drugs Market
1.1. Definition and Scope
1.1.1. Definition of Anti-Obesity Drugs
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Anti-Obesity Drugs Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Anti-Obesity Drugs Market By Drug Class
1.2.3. Anti-Obesity Drugs Market By Drug Type
1.2.4. Anti-Obesity Drugs Market By Distribution Channel
1.2.5. Anti-Obesity Drugs Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Source
2.2.2. Primary Source
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Anti-Obesity Drugs Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Anti-Obesity Drugs Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Price Trend of Key Raw Material
3.8.1. Raw Material Suppliers
3.8.2. Proportion of Manufacturing Cost Structure
3.8.2.1. Raw Material
3.8.2.2. Labor Cost
3.8.2.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2022
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2022
4.2. R&D Status of Major Manufacturers in 2022
CHAPTER 5. Anti-Obesity Drugs Market By Drug Class
5.1. Introduction
5.2. Anti-Obesity Drugs Revenue By Drug Class
5.2.1. Anti-Obesity Drugs Revenue (USD Billion) and Forecast, By Drug Class, 2020-2032
5.2.2. Centrally Acting Drugs
5.2.2.1. Centrally Acting Drugs Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. Peripherally Acting Drugs
5.2.3.1. Peripherally Acting Drugs Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Anti-Obesity Drugs Market By Drug Type
6.1. Introduction
6.2. Anti-Obesity Drugs Revenue By Drug Type
6.2.1. Anti-Obesity Drugs Revenue (USD Billion) and Forecast, By Drug Type, 2020-2032
6.2.2. OTC Drugs
6.2.2.1. OTC Drugs Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. Prescription Drugs
6.2.3.1. Prescription Drugs Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. Anti-Obesity Drugs Market By Distribution Channel
7.1. Introduction
7.2. Anti-Obesity Drugs Revenue By Distribution Channel
7.2.1. Anti-Obesity Drugs Revenue (USD Billion) and Forecast, By Distribution Channel, 2020-2032
7.2.2. Hospital Pharmacy
7.2.2.1. Hospital Pharmacy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.3. Online Pharmacy
7.2.3.1. Online Pharmacy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.4. Retail Pharmacy
7.2.4.1. Retail Pharmacy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 8. North America Anti-Obesity Drugs Market By Country
8.1. North America Anti-Obesity Drugs Market Overview
8.2. U.S.
8.2.1. U.S. Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
8.2.2. U.S. Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
8.2.3. U.S. Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
8.3. Canada
8.3.1. Canada Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
8.3.2. Canada Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
8.3.3. Canada Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
8.4. North America PEST Analysis
CHAPTER 9. Europe Anti-Obesity Drugs Market By Country
9.1. Europe Anti-Obesity Drugs Market Overview
9.2. U.K.
9.2.1. U.K. Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.2.2. U.K. Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
9.2.3. U.K. Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.3. Germany
9.3.1. Germany Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.3.2. Germany Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
9.3.3. Germany Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.4. France
9.4.1. France Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.4.2. France Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
9.4.3. France Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.5. Spain
9.5.1. Spain Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.5.2. Spain Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
9.5.3. Spain Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.6. Rest of Europe
9.6.1. Rest of Europe Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
9.6.2. Rest of Europe Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
9.6.3. Rest of Europe Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
9.7. Europe PEST Analysis
CHAPTER 10. Asia Pacific Anti-Obesity Drugs Market By Country
10.1. Asia Pacific Anti-Obesity Drugs Market Overview
10.2. China
10.2.1. China Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.2.2. China Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
10.2.3. China Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.3. Japan
10.3.1. Japan Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.3.2. Japan Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
10.3.3. Japan Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.4. India
10.4.1. India Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.4.2. India Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
10.4.3. India Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.5. Australia
10.5.1. Australia Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.5.2. Australia Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
10.5.3. Australia Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.6. South Korea
10.6.1. South Korea Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.6.2. South Korea Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
10.6.3. South Korea Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.7. Rest of Asia-Pacific
10.7.1. Rest of Asia-Pacific Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
10.7.2. Rest of Asia-Pacific Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
10.7.3. Rest of Asia-Pacific Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
10.8. Asia Pacific PEST Analysis
CHAPTER 11. Latin America Anti-Obesity Drugs Market By Country
11.1. Latin America Anti-Obesity Drugs Market Overview
11.2. Brazil
11.2.1. Brazil Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.2.2. Brazil Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
11.2.3. Brazil Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.3. Mexico
11.3.1. Mexico Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.3.2. Mexico Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
11.3.3. Mexico Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.4. Rest of Latin America
11.4.1. Rest of Latin America Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
11.4.2. Rest of Latin America Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
11.4.3. Rest of Latin America Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
11.5. Latin America PEST Analysis
CHAPTER 12. Middle East & Africa Anti-Obesity Drugs Market By Country
12.1. Middle East & Africa Anti-Obesity Drugs Market Overview
12.2. GCC
12.2.1. GCC Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
12.2.2. GCC Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
12.2.3. GCC Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.3. South Africa
12.3.1. South Africa Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
12.3.2. South Africa Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
12.3.3. South Africa Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.4. Rest of Middle East & Africa
12.4.1. Rest of Middle East & Africa Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Class, 2020-2032
12.4.2. Rest of Middle East & Africa Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Drug Type, 2020-2032
12.4.3. Rest of Middle East & Africa Anti-Obesity Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2020-2032
12.5. Middle East & Africa PEST Analysis
CHAPTER 13. Player Analysis Of Anti-Obesity Drugs Market
13.1. Anti-Obesity Drugs Market Company Share Analysis
13.2. Competition Matrix
13.2.1. Competitive Benchmarking Of Key Players By Price, Presence, Market Share, And R&D Investment
13.2.2. New Product Launches and Product Enhancements
13.2.3. Mergers And Acquisition In Global Anti-Obesity Drugs Market
13.2.4. Partnership, Joint Ventures and Strategic Alliances/Sales Agreements
CHAPTER 14. Company Profile
14.1. Novo Nordisk A/S
14.1.1. Company Snapshot
14.1.2. Business Overview
14.1.3. Financial Overview
14.1.3.1. Revenue (USD Billion), 2022
14.1.3.2. Novo Nordisk A/S 2022 Anti-Obesity Drugs Business Regional Distribution
14.1.4. Product/Service and Specification
14.1.5. Recent Developments & Business Strategy
14.2. Arena Pharmaceuticals, Inc.
14.3. VIVUS, Inc.
14.4. Orexigen Therapeutics, Inc. (acquired by Nalpropion Pharmaceuticals)
14.5. Eisai Co., Ltd.
14.6. Takeda Pharmaceutical Company Limited
14.7. Rhythm Pharmaceuticals, Inc.
14.8. Gelesis, Inc.
14.9. Zafgen, Inc.
14.10. Boehringer Ingelheim International GmbH
14.11. F. Hoffmann-La Roche Ltd.
14.12. AstraZeneca PLC
Frequently Asked Questions
What was the market size of the global anti-obesity drugs in 2022?
The market size of anti-obesity drugs was USD 2.1 Billion in 2022.
What is the CAGR of the global anti-obesity drugs market from 2023 to 2032?
The CAGR of anti-obesity drugs is 14.6% during the analysis period of 2023 to 2032.
Which are the key players in the anti-obesity drugs market?
The key players operating in the global market are including Novo Nordisk A/S, Arena Pharmaceuticals, Inc., VIVUS, Inc., Orexigen Therapeutics, Inc. (acquired by Nalpropion Pharmaceuticals), Eisai Co., Ltd., Takeda Pharmaceutical Company Limited, Rhythm Pharmaceuticals, Inc., Gelesis, Inc., Zafgen, Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., and AstraZeneca PLC.
Which region dominated the global anti-obesity drugs market share?
North America held the dominating position in anti-obesity drugs industry during the analysis period of 2023 to 2032.
Which region registered fastest CAGR from 2023 to 2032?
Asia-Pacific region exhibited fastest growing CAGR for market of anti-obesity drugs during the analysis period of 2023 to 2032.
What are the current trends and dynamics in the global anti-obesity drugs industry?
The current trends and dynamics in the anti-obesity drugs industry include rising global obesity rates, growing awareness of obesity-related health risks, and advances in drug development and research.
Which drug type held the maximum share in 2022?
The prescription drug type held the maximum share of the anti-obesity drugs industry.
Select Licence Type
Connect with our sales team
Why Acumen Research and Consulting
100%
Customer Satisfaction
24x7+
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
